[Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report]

Zhonghua Xue Ye Xue Za Zhi. 2021 Aug 14;42(8):690. doi: 10.3760/cma.j.issn.0253-2727.2021.08.015.

[Article in Chinese]

Authors

Y Song¹, Y R Zhang¹, Y Han¹, Y Wang¹, Y Q Li¹, Y Chai¹, P Y Zeng¹, L L Yue¹, C Y Wu¹

Affiliation

¹ Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou 730000, China.

PMID: 34547879
PMCID: PMC8501287
DOI: 10.3760/cma.j.issn.0253-2727.2021.08.015

No abstract available

Publication types

Case Reports

MeSH terms

Eosinophilia* / drug therapy
Humans
Janus Kinase 2 / genetics
Myeloproliferative Disorders* / drug therapy
Neoplasms*
Nitriles
Oncogene Proteins, Fusion
Pyrazoles / therapeutic use
Pyrimidines

Substances

Nitriles
Oncogene Proteins, Fusion
PCM1-JAK2 fusion protein, human
Pyrazoles
Pyrimidines
ruxolitinib
JAK2 protein, human
Janus Kinase 2

Grants and funding

基金项目：甘肃省自然科学基金（18JR3RA320）；兰州市科技发展指导性计划（2019-ZD-65）；兰州大学第二医院萃英科技创新计划（CY2018-MS07）